Iscalimab (CFZ533) Update
XOMA Royalty Corporation (XOMA)
Last xoma royalty corporation earnings: 3/10 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.xoma.com/investor-relations
Company Research
Source: GlobeNewswire
EMERYVILLE, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- As part of its R&D Day on December 5, 2019, Novartis highlighted the progress that has been made on iscalimab (CFZ533), a product candidate, for which XOMA (NASDAQ: XOMA) has the potential to earn royalties that are tiered from a mid-single to a low teens percentage rate based on sales levels, if this investigational compound is approved and commercialized. Novartis dedicated eight (8) slides to the iscalimab update. Please find the Novartis R&D Day Presentation on the Novartis website (slide numbers 1, 2, 64-71). Additionally, the relevant slides can be found on our website at www.xoma.com. Iscalimab, which originated from XOMA’s research collaboration with Chiron (acquired by Novartis), is a fully human monoclonal antibody blocking the CD40 – CD154 signaling pathway. Please note: Iscalimab (CFZ533) is an investigational compound. There is no guarantee that iscalimab will become commercially available. About XOMA Corpora
Show less
Read more
Impact Snapshot
Event Time:
XOMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XOMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XOMA alerts
High impacting XOMA Royalty Corporation news events
Weekly update
A roundup of the hottest topics
XOMA
News
- XOMA Corp - 8.375% DP PFD B declares $0.5234 dividend [Seeking Alpha]Seeking Alpha
- XOMA Royalty Declares Quarterly Preferred Stock DividendsGlobeNewswire
- XOMA Co. (NASDAQ: XOMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $123.00 price target on the stock.MarketBeat
- XOMA Co. (NASDAQ: XOMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $123.00 price target on the stock, up previously from $117.00.MarketBeat
- XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its PortfolioGlobeNewswire
XOMA
Earnings
- 11/7/24 - Miss
XOMA
Sec Filings
- 12/2/24 - Form 8-K
- 11/13/24 - Form 4
- 11/13/24 - Form 4
- XOMA's page on the SEC website